Sugi Predict

Sugi Predict / Targets / ACP1

ACP1

Low molecular weight phosphotyrosine protein phosphatase · P24666 · ACP1 on Sugi Atlas →

44,617 patent compounds predicted against ACP1, 23,679 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL491641 SCHEMBL491641 0.70 14/20
SCHEMBL805612 SCHEMBL805612 0.56 13/20
SCHEMBL373863 SCHEMBL373863 0.51 13/20
SCHEMBL491669 SCHEMBL491669 0.64 11/20
SCHEMBL786653 SCHEMBL786653 0.61 10/20
SCHEMBL786208 SCHEMBL786208 0.53 10/20
SCHEMBL786413 SCHEMBL786413 0.57 9/20
SCHEMBL581226 SCHEMBL581226 0.38 8/20
SCHEMBL311257 SCHEMBL311257 0.58 7/20
SCHEMBL801844 SCHEMBL801844 0.46 7/20
SCHEMBL311868 SCHEMBL311868 0.62 6/20
SCHEMBL312370 SCHEMBL312370 0.61 6/20
SCHEMBL311349 SCHEMBL311349 0.58 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL312145) 0.57 6/20
SCHEMBL644347 SCHEMBL644347 0.39 6/20
SCHEMBL581145 SCHEMBL581145 0.38 6/20
SCHEMBL197822 SCHEMBL197822 0.36 6/20
SCHEMBL786737 SCHEMBL786737 0.61 5/20
SCHEMBL785632 SCHEMBL785632 0.61 5/20
SCHEMBL311942 SCHEMBL311942 0.59 5/20

Clinical trials — most relevant to ACP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery EARLY_PHASE1COMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Phosphoproteomic Profile of Children With Down Syndrome nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life nanCOMPLETED
S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia nanCOMPLETED
Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas nanNOT_YET_RECRUITING
Markers for Early Detection of Prostate Cancer nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Determining the Muscle Anabolic Properties of Phosphatidic Acid. nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Improving the Diagnosis of Common Variable Immune Deficiency nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ACP1 binder may also engage these)

ProteinNameSimilarity
Q5REM7 — 1.000 Q5REM7 →
P41498 — 0.994 P41498 →
Q9D358 — 0.992 Q9D358 →
Q5ZKG5 — 0.973 Q5ZKG5 →
P11064 — 0.937 P11064 →
Q5HZM6 — 0.921 Q5HZM6 →
Q6NVL5 — 0.920 Q6NVL5 →
Q5RIC0 — 0.920 Q5RIC0 →
Q9H9T3 — 0.920 Q9H9T3 →
Q6NRQ7 — 0.919 Q6NRQ7 →
P81693 — 0.919 P81693 →
Q5ZHS1 — 0.917 Q5ZHS1 →
Q2KJ61 — 0.917 Q2KJ61 →
Q5ZJQ7 — 0.914 Q5ZJQ7 →
Q17QL1 — 0.911 Q17QL1 →
Q5ZJX1 — 0.910 Q5ZJX1 →
Q8TDQ7 — 0.910 Q8TDQ7 →
Q27HV0 — 0.909 Q27HV0 →
Q17QI2 — 0.909 Q17QI2 →
Q5ZIH0 — 0.909 Q5ZIH0 →
Q9PW38 — 0.908 Q9PW38 →
P56558 — 0.908 P56558 →
OGT UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 0.907 landscape →
Q8CGY8 — 0.907 Q8CGY8 →
A4IHW6 — 0.907 A4IHW6 →
Q9CQ65 — 0.907 Q9CQ65 →
Q9CY97 — 0.907 Q9CY97 →
P79101 — 0.907 P79101 →
Q9JIB4 — 0.906 Q9JIB4 →
Q0IID9 — 0.906 Q0IID9 →